- Palatin Technologies ( NYSE: PTN ) shares gained ~8% pre-market on Tuesday after the biopharmaceutical company reported prelim Q4 sales for its Vyleesi product.
- Vyleesi, said to be the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized HSDD (hypoactive sexual desire disorder), experienced 225% growth in net product revenue over the prior quarter. Revenue grew 600% when compared to the same quarter in 2021.
- Gross product sales increased 75% over the prior quarter and 90% over the comparable quarter in 2021.
- Prescriptions dispensed increased 45% over prior quarter and 50% over the comparable quarter in 2021.
- CEO Carl Spana said, "Our operating results, which includes significant increases across all sales and distribution value metrics, compared to both the prior quarter and the comparable quarter in 2021, continue to demonstrate Vyleesi's potential within the female sexual healthcare market."
For further details see:
Palatin expects 225% sequential growth in Vyleesi Q4 sales